Evidence map›Paper›PMID 33704530›Full record

Trial reportAnnals of hematology2021

Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort.

Magdalena M Brune, Georg Stüssi, Pontus Lundberg, Visar Vela, Dominik Heim, Markus G Manz, Eugenia Haralambieva, Thomas Pabst, Yara Banz, Mario Bargetzi and 12 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 3 countries.

Magdalena M BruneInstitute of Medical Genetics and Pathology, University Hospital Basel, Schoenbeinstrasse 40, 4031, Basel, Switzerland.
Georg StüssiOncological Institute of Italian Switzerland, Via Ospedale, 6500, Bellinzona, Switzerland.
Pontus LundbergDivision of Hematology, Department of Medicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland.
Visar VelaInstitute of Medical Genetics and Pathology, University Hospital Basel, Schoenbeinstrasse 40, 4031, Basel, Switzerland.
Dominik HeimDivision of Hematology, Department of Medicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland.
Markus G ManzDepartment of Medical Oncology and Hematology, University and University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland.
Eugenia HaralambievaInstitute of Pathology and Molecular Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091, Zürich, Switzerland.
Thomas PabstDepartment of Medical Oncology, Inselspital, University Hospital and University of Bern, 3010, Bern, Switzerland.
Yara BanzInstitute of Pathology, University of Bern, Murtenstrasse 31, 3008, Bern, Switzerland.
Mario BargetziClinic for Oncology, Hematology and Transfusion Medicine, Cantonal Hospital Aarau AG, Tellstrasse 25, 5001, Aarau, Switzerland.
Rainer GrobholzInstitute of Pathology, Cantonal Hospital Aarau AG, Tellstrasse 25, 5001, Aarau, Switzerland.
Martin FehrClinic for Medical Oncology and Hematology, Cantonal Hospital St. Gallen, Rorschacher Strasse 95, 9007, St. Gallen, Switzerland.
Sergio CogliattiInstitute of Pathology, Cantonal Hospital St. Gallen, Rorschacher Strasse 95, 9007, St. Gallen, Switzerland.
Gert J OssenkoppeleDepartment of Hematology, Amsterdam University Medical Center, Cancer Center Amsterdam, VU University Medical Center, De Boelelaan 1118, 1182, Amsterdam, DB, Netherlands.
Bob LöwenbergDepartment of Hematology, Erasmus University Rotterdam, Dr. Molewaterplein 50, 3000, Rotterdam, CA, Netherlands.
Christina Biaggi RudolfSwiss Group for Clinical Cancer Research (SAKK), Coordinating Center, Effingerstrasse 33, CH-3008, Bern, Switzerland.
Qiyu LiSwiss Group for Clinical Cancer Research (SAKK), Coordinating Center, Effingerstrasse 33, CH-3008, Bern, Switzerland.
Jakob PasswegDivision of Hematology, Department of Medicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland.
Luca MazzuchelliCantonal Institute of Pathology, Via Selva 24, 6601, Locarno, Switzerland.
Michael Medinger *Division of Hematology, Department of Medicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland. michael.medinger@usb.ch.ORCID http://orcid.org/0000-0003-0427-7747
Alexandar Tzankov *Institute of Medical Genetics and Pathology, University Hospital Basel, Schoenbeinstrasse 40, 4031, Basel, Switzerland. alexandar.tzankov@usb.ch.ORCID https://orcid.org/0000-0002-1100-3819
Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK)
University Hospital of Basel · CHKantonsspital Aarau · CHSwiss Group For Clinical Cancer Research · CHUniversity Hospital of Zurich · CHUniversity of Bern · CHUniversity of St.Gallen · CHErasmus University Rotterdam · NLIstituto Cantonale di Patologia · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This translational study aimed at gaining insight into the effects of lenalidomide in acute myeloid leukemia (AML). Forty-one AML patients aged 66 or older of the Swiss cohort of the HOVON-103 AML/SAKK30/10 study were included. After randomization, they received standard induction chemotherapy with or without lenalidomide. Bone marrow biopsies at diagnosis and before the 2nd induction cycle were obtained to assess the therapeutic impact on leukemic blasts and microenvironment. Increased bone marrow angiogenesis, as assessed by microvessel density (MVD), was found at AML diagnosis and differed significantly between the WHO categories. Morphological analysis revealed a higher initial MVD in AML with myelodysplasia-related changes (AML-MRC) and a more substantial decrease of microvascularization after lenalidomide exposure. A slight increase of T-bet-positive TH1-equivalents was identifiable under lenalidomide. In the subgroup of patients with AML-MRC, the progression-free survival differed between the two treatment regimens, showing a potential but not significant benefit of lenalidomide. We found no correlation between the cereblon genotype (the target of lenalidomide) and treatment response or prognosis. In conclusion, addition of lenalidomide may be beneficial to elderly patients suffering from AML-MRC, where it leads to a reduction of microvascularization and, probably, to an intensified specific T cell-driven anti-leukemic response.

Indexed as

AgedAngiogenesis InhibitorsBone MarrowCohort StudiesFemaleHumansLenalidomideLeukemia, Myeloid, AcuteMaleNeovascularization, PathologicTumor MicroenvironmentAngiogenesis InhibitorsLenalidomideAcute myeloid leukemiaBone marrow microenvironmentCereblonLenalidomideMicrovessel densityT cells

Identifiers

PMID33704530
PMCPMC8043896
OpenAlexW3134234338

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.